NU7441 (KU-57788)

Catalog No.S2638

Molecular Weight(MW): 413.49

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Size

Price

Stock

Quantity

5mg	USD 70	In stock
10mg	USD 120	In stock
50mg	USD 370	In stock
200mg	USD 970	In stock
Bulk Size	Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: (510) 833-3558 (UCSF/UC Berkeley) | (713) 732-9637 (Stanford) sales@selleckchem.com

Cited by 15 Publications

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109

Mol Cancer Res, 2015, 13(1):120-9

PubMed:

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669
Biosci Rep, 2014, 34(3)

PubMed: 24844881

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed:

Uppsala University, 2014, Department of Radiology

PubMed:

4 Customer Reviews

Cells were treated with cisplatin under the following conditions: pretreatment with Nu7026 (Nu7026, 26) or Nu7441 (Nu7441, 41). Before DNA damage, wortmannin was applied at 100 nM for 30 min, Nu7026 at 10 uM for 1 h, Nu7441 at 1 uM for 1 h. Accompanying quantifications of the adjusted nucleolar EU fluorescence are shown. Each condition was normalized to cells treated with DMSO or indicated inhibitors without DNA damaging treatment. Two-way ANOVA was followed by Holm-Sidak's test for the comparison of cells with and without inhibitors. *, **, *** represent P ≤ 0.05, 0.01, 0.001, respectively.

Nucleic Acids Res 2013 41(15), 7378-86. NU7441 (KU-57788) purchased from Selleck.

Confocal immunostaining of S2056 phosphorylation of DNA-PKcs following radiation in HEK 293T and p18CycE-expressing cells.

Nucleic Acids Res 2013 41, 10157-69. NU7441 (KU-57788) purchased from Selleck.
Validation of activity and specificity of chemical inhibitors of; ATM, ATR, and DNAPK. H460 cells were treated with 1 uM camptothecin (CPT) or 20 ug/ml bleomycin for 1 h in the presence of the indicated inhibitors: DNAPK-i1—NU7026, DNAPK-i2—NU7441. MSH6, fibrillarin, and tubulin were used as loading controls.Effects of DNAPK inhibitors on its autophosphorylation in bleomycin-treated cells.

Toxicol Sci 2014 10.1093/toxsci/kfu207. NU7441 (KU-57788) purchased from Selleck.

After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of NU-7441 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. NU7441 (KU-57788) purchased from Selleck.

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Targets

DNA-PK ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)	PI3K ^[1] (Cell-free assay)	ATM ^[1] (Cell-free assay)	ATR ^[1] (Cell-free assay)
14 nM	1.7 μM	5 μM	>100 μM	>100 μM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1770	NVPic5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jnS2lEPTB;MD6wNlE1OyEQvF2=	MXnTRW5ITVJ?
A172	M3T2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXiySHVUUUN3ME2wMlE2OzF4IN88US=>	MUPTRW5ITVJ?
NCI-H526	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\jfmlEPTB;MD6yPFQxPyEQvF2=	NVPUc\|k{W0GQR1XS
HDLM-2	M3rtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjOOnJVUUN3ME2wMlMzOzR3IN88US=>	NHvPXINUSU6JRWK=
HuO-3N1	NH3qOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;zTWM2OD1yLkS2OlM3KM7:TR?=	NGX6XI5USU6JRWK=
NCI-SNU-1	NF3EfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvPbZBlUUN3ME2wMlYxQTl2IN88US=>	M1PTN3NCVkeHUh?=
SK-N-AS	NX3RN3d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwNkKyNVYh\|ryP	NX7SeJBuW0GQR1XS
LoVo	NH7CXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwOE[3OFkh\|ryP	Ml7kV2FPT0WU
LAMA-84	NGjZeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPiTWM2OD1yLkm4PFM{KM7:TR?=	NX3adGJqW0GQR1XS
CTB-1	M1TwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOwNZpKSzVyPUGuNVE2PDZizszN	NIfFZVhUSU6JRWK=
KP-N-YS	NIS1U2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\zN5BRUUN3ME2xMlE1OjNzIN88US=>	MmDEV2FPT0WU
HH	M3\WfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\ON2lEPTB;MT6xPFA6OyEQvF2=	MoG5V2FPT0WU
CHL-1	NF\Wfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i1UmlEPTB;MT6yNVM3QCEQvF2=	MULTRW5ITVJ?
NB7	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFwMkS3OFUh\|ryP	MXXTRW5ITVJ?
HL-60	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDke45KSzVyPUGuN\|gyQSEQvF2=	NIrhXlBUSU6JRWK=
639-V	NXzyOYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwNESxNlgh\|ryP	M{PpeHNCVkeHUh?=
NCI-H1793	NVrMWHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;tTWM2OD1zLkS1PFQh\|ryP	M2D6dnNCVkeHUh?=
NEC8	M{nDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHnTWM2OD1zLkW1N\|Uh\|ryP	MoL5V2FPT0WU
PA-1	NULK[GtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;hWWc6UUN3ME2xMlU5Ojl2IN88US=>	MmfGV2FPT0WU
D-423MG	M17nXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwNkmzOlEh\|ryP	NYD3VZQ{W0GQR1XS
NCI-H292	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFwN{SwNVMh\|ryP	M1XsSnNCVkeHUh?=
SK-MEL-1	NGj5UWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\mfmlEPTB;MT63PVQ4QSEQvF2=	M{PZXHNCVkeHUh?=
LB2241-RCC	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2WwTmlEPTB;Mj6xOFE1PiEQvF2=	NFmyRoNUSU6JRWK=
SK-MEL-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[5fYFKSzVyPUKuNVY1QSEQvF2=	MUPTRW5ITVJ?
MHH-PREB-1	NEHW[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDhTWM2OD1{LkG2OlA6KM7:TR?=	NWTvTFlpW0GQR1XS
BFTC-905	M1r1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH5T5lKSzVyPUKuNVY3QDdizszN	NF[yT3hUSU6JRWK=
Ramos-2G6-4C10	M17yeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTEVJRKSzVyPUKuNVk6ODlizszN	M3;2TnNCVkeHUh?=
G-361	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\VV3BKSzVyPUKuNlE3QCEQvF2=	NXPldmJvW0GQR1XS
MOLT-4	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDyTWM2OD1{LkKxPFg5KM7:TR?=	Mn3LV2FPT0WU
DEL	NXfwVYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LQSWlEPTB;Mj6zOVU3PCEQvF2=	NUP4O5dQW0GQR1XS
MV-4-11	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nNU2lEPTB;Mj6zO\|M6KM7:TR?=	NUDMfFVtW0GQR1XS
SK-NEP-1	MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX64WIp4UUN3ME2yMlM5Pzh\|IN88US=>	M4XvZ3NCVkeHUh?=
RS4-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjmcnVvUUN3ME2yMlU3ODJ\|IN88US=>	MWTTRW5ITVJ?
HuH-7	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO1PYpKSzVyPUKuOVY4ODJizszN	MnTIV2FPT0WU
A101D	NF;EWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TENWlEPTB;Mj62NVM{QCEQvF2=	M4H1SnNCVkeHUh?=
KG-1	M4T6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjVXJBKSzVyPUKuOlc6OjRizszN	NEPoZ2hUSU6JRWK=
KALS-1	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO2ephGUUN3ME2yMlY6PjN\|IN88US=>	NUC4O2Z1W0GQR1XS
VMRC-RCZ	M{\BUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTJwN{ezNlgh\|ryP	M4\GNHNCVkeHUh?=
SK-UT-1	NFvvRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHyzcm1KSzVyPUOuNVU{OSEQvF2=	M2e2eHNCVkeHUh?=
SW962	NFXVZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTNwMkCzOVIh\|ryP	MoTLV2FPT0WU
DBTRG-05MG	M2PhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHs[\|BKSzVyPUOuNlgxQDVizszN	NUHuN2JHW0GQR1XS
PANC-08-13	NXjTZZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIniWZVKSzVyPUOuOFEzPzhizszN	MVnTRW5ITVJ?
QIMR-WIL	NGnSUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDxRWdKSzVyPUOuOFE{PDFizszN	M2fjXnNCVkeHUh?=
SK-MEL-30	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTNwNEK1PVgh\|ryP	MYHTRW5ITVJ?
697	NG[0VI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;Cd2lEPTB;Mz60OFk6OyEQvF2=	NWPPZ3k3W0GQR1XS
NY	NYnoSHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPIeJc4UUN3ME2zMlQ2ODJ{IN88US=>	M1PQ[nNCVkeHUh?=
ES7	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;SSlJKSzVyPUOuOFY4OjlizszN	NF70b3ZUSU6JRWK=
JVM-3	NWfaVGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W1VmlEPTB;Mz60PFA4PyEQvF2=	MX3TRW5ITVJ?
U031	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M364d2lEPTB;Mz61PVM3QCEQvF2=	Mn\ZV2FPT0WU
BHT-101	NHHIfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjXdolkUUN3ME2zMlU6QTh3IN88US=>	MmT3V2FPT0WU
8305C	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTNwNkG3N\|Yh\|ryP	MX\TRW5ITVJ?
MG-63	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTwbVNKSzVyPUOuOlI3PzZizszN	NFjsUHRUSU6JRWK=
NOS-1	NGrVb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfCTWM2OD1\|Lk[1N\|EzKM7:TR?=	M2TEcHNCVkeHUh?=
YH-13	NUDJNJRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;jTWM2OD1\|Lki3NVg6KM7:TR?=	MmD2V2FPT0WU
LXF-289	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfTd\|VKSzVyPUOuPVExPDFizszN	NX;vW2lWW0GQR1XS
GOTO	M3rEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fLZmlEPTB;Mz65NVQ6KM7:TR?=	MXzTRW5ITVJ?
EKVX	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\KTWM2OD12LkKyOVI1KM7:TR?=	MnvYV2FPT0WU
CAL-51	NEP4[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e0PWlEPTB;ND6yOFg2PCEQvF2=	NHrzfndUSU6JRWK=
AN3-CA	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjRTWM2OD12LkK1PFE{KM7:TR?=	M4TpUXNCVkeHUh?=
IA-LM	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTRwMke5N\|Uh\|ryP	NX7XdJFTW0GQR1XS
KU-19-19	NYnhZYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LBVmlEPTB;ND6zNlkzOSEQvF2=	MXzTRW5ITVJ?
A704	M{S0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYKzb3ZuUUN3ME20MlQxQDh6IN88US=>	NH3GXFBUSU6JRWK=
RH-18	NFfSRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXKUWgyUUN3ME20MlQ1QTV\|IN88US=>	NGjpRnFUSU6JRWK=
IST-MEL1	NFn0TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnoPXNKSzVyPUSuOVgzPjNizszN	M4LTfHNCVkeHUh?=
LU-134-A	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUOxNmJ4UUN3ME20MlU6Pjh3IN88US=>	MXHTRW5ITVJ?
SF126	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDKVWZKSzVyPUSuOlA4OTVizszN	NETSU45USU6JRWK=
EFO-27	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjGZWFKSzVyPUSuOlY2OjVizszN	M{G2WXNCVkeHUh?=
SN12C	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PMbGlEPTB;ND63NVg6QCEQvF2=	MoXEV2FPT0WU
L-363	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTRwN{exNVYh\|ryP	M1\mZnNCVkeHUh?=
MEL-HO	NWDuc2ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHETWM2OD12Lke3PVg6KM7:TR?=	NWW5NYFkW0GQR1XS
TYK-nu	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfzdnRxUUN3ME20MlgxOTJ6IN88US=>	MWXTRW5ITVJ?
MDA-MB-415	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHwTWM2OD13LkCwN\|E1KM7:TR?=	MUDTRW5ITVJ?
HCC70	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTVwMEO5N\|kh\|ryP	MUjTRW5ITVJ?
IGROV-1	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXwcoxKSzVyPUWuNlUzQTJizszN	NHGyO2tUSU6JRWK=
NCI-H1355	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTVwMkm2JO69VQ>?	MUDTRW5ITVJ?
23132-87	M2ftUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme3TWM2OD13LkOyNFI1KM7:TR?=	NEjNSI9USU6JRWK=
NB69	M4L6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XyPWlEPTB;NT6zNlQzKM7:TR?=	NVLtRVZ2W0GQR1XS
HSC-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTVwNEG3O\|Mh\|ryP	NX74XoV{W0GQR1XS
KYSE-410	NInxNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\iTmlEPTB;NT60O\|Y{PiEQvF2=	M13sRXNCVkeHUh?=
GCIY	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEKwWZJKSzVyPUWuOVE{PzhizszN	M1S1NnNCVkeHUh?=
A427	M4KzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonWTWM2OD13LkWzOlYyKM7:TR?=	MWDTRW5ITVJ?
ChaGo-K-1	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfTeGFKSzVyPUWuOVY2QTlizszN	Mn74V2FPT0WU
PFSK-1	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfVfoNxUUN3ME21MlYzOTl2IN88US=>	M3PuXnNCVkeHUh?=
MLMA	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfab3FKSzVyPUWuPFM3ODZizszN	M2fqNXNCVkeHUh?=
RVH-421	NFfPNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjC[Ho5UUN3ME22MlA4OzN6IN88US=>	M3Xjb3NCVkeHUh?=
LB1047-RCC	NH;ib5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTZwMUe1NlIh\|ryP	MWTTRW5ITVJ?
MHH-NB-11	M4DndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnkRpdYUUN3ME22MlMzPzJzIN88US=>	M4fuXHNCVkeHUh?=
J-RT3-T3-5	M2fjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXX6[WFEUUN3ME22MlY{OjlzIN88US=>	NFjIV3hUSU6JRWK=
UM-UC-3	M3X2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr1TWM2OD14Lk[0N\|M1KM7:TR?=	NHPob\|FUSU6JRWK=
IST-SL1	NGD0W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTZwNkmzOlkh\|ryP	MYDTRW5ITVJ?
NB14	M{i2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTZwN{m3OlEh\|ryP	NF7HXmFUSU6JRWK=
NBsusSR	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFewUlZKSzVyPU[uPFI2ODJizszN	NH7SXFJUSU6JRWK=
D-263MG	NVHoVJZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHTTWM2OD14LkmxNFY5KM7:TR?=	MX7TRW5ITVJ?
NCI-H2347	NHfLVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[1ZYhSUUN3ME22Mlk{OjF\|IN88US=>	NEnKUlBUSU6JRWK=
ES8	MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonrTWM2OD14Lkm3OVg5KM7:TR?=	NUXRU21vW0GQR1XS
786-0	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPIOJpOUUN3ME23MlA6Pzh4IN88US=>	MUfTRW5ITVJ?
EPLC-272H	M4HVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnzVFNKSzVyPUeuNVYzPDZizszN	MVXTRW5ITVJ?
CAPAN-1	NGf5e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnX3TWM2OD15LkK0N\|U6KM7:TR?=	MojBV2FPT0WU
NCI-H82	NUfOcVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1G5XWlEPTB;Nz6yOlY2QSEQvF2=	NUj2WYU1W0GQR1XS
G-402	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTdwM{CwOVEh\|ryP	NV7rc45XW0GQR1XS
SW982	M{XZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVv2RodRUUN3ME23MlMxOjB\|IN88US=>	MYnTRW5ITVJ?
OVCAR-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPMfVBKSzVyPUeuN\|E{OjhizszN	NHfufo5USU6JRWK=
KARPAS-299	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXWwOoZVUUN3ME23MlMzPjJ{IN88US=>	MWnTRW5ITVJ?
MIA-PaCa-2	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULoeVZOUUN3ME23MlM3QDJ\|IN88US=>	NHLIUmxUSU6JRWK=
AU565	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nyfWlEPTB;Nz61PVg{OyEQvF2=	NX3vXJA{W0GQR1XS
GAMG	M2f3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTdwNkSxN\|Eh\|ryP	NV\FcZVJW0GQR1XS
HuO9	M1rmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTdwN{G3OFMh\|ryP	NYLOZVQzW0GQR1XS
ACN	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnizTWM2OD15Lke0N\|Mh\|ryP	MoD0V2FPT0WU
RO82-W-1	NIHGe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\N[3pOUUN3ME23Mlc1PTN\|IN88US=>	MVvTRW5ITVJ?
NKM-1	NY\hTpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\FclFKSzVyPUeuO\|Q6PTVizszN	NYnucpBpW0GQR1XS
CAL-12T	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj6bpFKSzVyPUeuPVQ{PTJizszN	NU\EV\|ZrW0GQR1XS
FADU	NHv0TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRThwMEO2OVQh\|ryP	MkTpV2FPT0WU
NCI-H28	NV\l[GNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXxc\|VuUUN3ME24MlE3QTZ{IN88US=>	Mn;rV2FPT0WU
LCLC-97TM1	NXfLeGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrOTWM2OD16LkKxNVIzKM7:TR?=	NXv6eIpjW0GQR1XS
CHP-134	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml35TWM2OD16LkK0NVg2KM7:TR?=	NVjLPJZYW0GQR1XS
HT-1080	NWL1TWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXmRnBCUUN3ME24MlI2ODl\|IN88US=>	MmXWV2FPT0WU
PC-3	M4XFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjBSZZ{UUN3ME24MlI4Ozl{IN88US=>	M{HkXnNCVkeHUh?=
SNU-449	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHi1RY1KSzVyPUiuNlc6OyEQvF2=	M4LycXNCVkeHUh?=
VA-ES-BJ	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPpTWM2OD16LkO0Olg3KM7:TR?=	MnLpV2FPT0WU
HT	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLPTWM2OD16LkO2OFkh\|ryP	MoTsV2FPT0WU
HOS	M{jaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jPW2lEPTB;OD6zO\|U5QSEQvF2=	MXzTRW5ITVJ?
KNS-62	M2rW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRThwM{e3OlIh\|ryP	MVrTRW5ITVJ?
OAW-42	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fYPWlEPTB;OD65OVk3PCEQvF2=	NEnIdZdUSU6JRWK=
A549	M2HU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzETWM2OD17LkC5OlEzKM7:TR?=	NEnHW3RUSU6JRWK=
CAKI-1	NULqNGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHteI1KSzVyPUmuNVY3OSEQvF2=	NGjufZRUSU6JRWK=
HCC1937	MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTlwNkm4OlUh\|ryP	Mni4V2FPT0WU
GI-ME-N	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jCUGlEPTB;OT63NFE{PyEQvF2=	M1;w[3NCVkeHUh?=
DU-4475	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTlwOU[5N\|kh\|ryP	MVjTRW5ITVJ?
EM-2	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P4bmlEPTB;MUCuNlQzPiEQvF2=	MmjlV2FPT0WU
NCI-H1755	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfvZ5lKSzVyPUGwMlI1OjhizszN	M3XKUXNCVkeHUh?=
NCI-H1437	NFrUZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTFyLkW3NlUh\|ryP	MYHTRW5ITVJ?
VM-CUB-1	NV7zT3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP6TWM2OD1zMD62NVY1KM7:TR?=	NILTSlVUSU6JRWK=
A2058	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfCR\|hjUUN3ME2xNE43PDB2IN88US=>	M2XFTXNCVkeHUh?=
BPH-1	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTFyLkexOFUh\|ryP	NULXeWg4W0GQR1XS
NB5	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHaTWM2OD1zMD63OVU6KM7:TR?=	Mn;VV2FPT0WU
G-401	M4\PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTFyLke2NlYh\|ryP	MmTBV2FPT0WU
CAL-72	NXnCfVEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTFyLkiwPVQh\|ryP	NHHSb4hUSU6JRWK=
SK-MEL-28	NV36b4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvqXVZKSzVyPUGwMlgzODJizszN	M4\pfHNCVkeHUh?=
C32	M3;VZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHWwT3dKSzVyPUGwMlg{PDdizszN	NXHOR\|RvW0GQR1XS
NCI-H1155	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Gxb2lEPTB;MUCuPFM4PiEQvF2=	NHnDNpFUSU6JRWK=
BB49-HNC	NUL5Z255T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTFyLki1PFYh\|ryP	NVX2VXBoW0GQR1XS
GMS-10	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LafGlEPTB;MUCuPFk4OSEQvF2=	NEnDTWlUSU6JRWK=
K5	NVLTOoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfnbW01UUN3ME2xNE46ODdzIN88US=>	NEDZVHJUSU6JRWK=
OS-RC-2	M3X3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTFzLkC1OVkh\|ryP	M1qxXXNCVkeHUh?=
HTC-C3	NUPhO49HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nGfmlEPTB;MUGuNFcyPCEQvF2=	MWDTRW5ITVJ?
LB996-RCC	M1r6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:4PFY4UUN3ME2xNU4xPzJ\|IN88US=>	MVnTRW5ITVJ?
NCI-H1563	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXiTWM2OD1zMT6xNFEyKM7:TR?=	M4nKS3NCVkeHUh?=
CAL-54	M2LyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX70PHNQUUN3ME2xNU41QDFzIN88US=>	M37v[3NCVkeHUh?=
WM-115	NUTa[WhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXjTWM2OD1zMT62PFI1KM7:TR?=	NXfjcYc4W0GQR1XS
COLO-684	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTFzLkeyOlch\|ryP	NVLzVZhuW0GQR1XS
HOP-62	M3vzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Hh[mlEPTB;MUGuO\|UxQCEQvF2=	NXroRlRkW0GQR1XS
NCI-H650	NULlb4hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFzLki5OlEh\|ryP	MWPTRW5ITVJ?
TE-11	NHvRNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\STWM2OD1zMT65N\|E2KM7:TR?=	MUDTRW5ITVJ?
COLO-679	NVO2blNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1i5[2lEPTB;MUGuPVQ3KM7:TR?=	NFP4VpFUSU6JRWK=
FTC-133	NHf5XYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\kdmlEPTB;MUKuNFA4PiEQvF2=	MVrTRW5ITVJ?
D-283MED	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS2cZRKSzVyPUGyMlA2PjlizszN	MWfTRW5ITVJ?
SK-PN-DW	MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1y1cGlEPTB;MUKuNVkxOiEQvF2=	MnP4V2FPT0WU
BALL-1	M1faUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;UXXhqUUN3ME2xNk4zPjZ{IN88US=>	MW\TRW5ITVJ?
GT3TKB	NXX6Nm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnrTWM2OD1zMj6zNFc1KM7:TR?=	NUHpTYR7W0GQR1XS
HOP-92	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jEd2lEPTB;MUKuOVI{OyEQvF2=	MUHTRW5ITVJ?
M14	M2[5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[3[oNKSzVyPUGzMlA{OzVizszN	MlfWV2FPT0WU
SKG-IIIa	NYfZW2hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTF\|LkC1OVQh\|ryP	NIniR5JUSU6JRWK=
Becker	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDsRVhKSzVyPUGzMlA2QCEQvF2=	NEKxTVlUSU6JRWK=
ES5	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTF\|LkGzOVYh\|ryP	MXfTRW5ITVJ?
NCI-H2030	NX\Nc5FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrwTWM2OD1zMz6yNFYzKM7:TR?=	NXf4NVN4W0GQR1XS
SNU-423	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\2OJI4UUN3ME2xN{4{QDFizszN	M3;zd3NCVkeHUh?=
CP50-MEL-B	NULQS2syT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTF\|Lk[yN\|Ih\|ryP	MYnTRW5ITVJ?
NCI-H1092	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\hPI5KSzVyPUGzMlc1PzVizszN	MoHvV2FPT0WU
8-MG-BA	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nuT2lEPTB;MUOuO\|UyOyEQvF2=	MlfFV2FPT0WU
CAL-27	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGC1RXVKSzVyPUG0MlA4OjdizszN	MYDTRW5ITVJ?
AGS	NHG5cW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DPSWlEPTB;MUSuNVMyQSEQvF2=	NHT3eZlUSU6JRWK=
MZ2-MEL	M2LDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH1TWM2OD1zND6xOFg5KM7:TR?=	M4Cx[XNCVkeHUh?=
BFTC-909	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH6TWM2OD1zND61NFU2KM7:TR?=	NFT5UIxUSU6JRWK=
D-566MG	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHIdm1OUUN3ME2xOE44PzB4IN88US=>	NHjx[\|RUSU6JRWK=
MZ7-mel	M2i5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3zcWtpUUN3ME2xOU4yODZ5IN88US=>	NVn6dIQxW0GQR1XS
TE-5	NULZUWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHrd2VSUUN3ME2xOU4zOzN\|IN88US=>	M2nMNHNCVkeHUh?=
647-V	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF3LkK3NFUh\|ryP	MVvTRW5ITVJ?
DMS-114	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LIfmlEPTB;MUWuN\|I6OSEQvF2=	MkjNV2FPT0WU
ME-180	M{K5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTF3LkS3PFMh\|ryP	MXLTRW5ITVJ?
MS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfu[Gd2UUN3ME2xOU42PjJ\|IN88US=>	NFLGT3VUSU6JRWK=
NUGC-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PuUGlEPTB;MUWuOlI1PSEQvF2=	NXTJZVhZW0GQR1XS
GB-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTF3Lk[0N\|ch\|ryP	MYnTRW5ITVJ?
LOXIMVI	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTF3Lki5NVkh\|ryP	MmX4V2FPT0WU
NCI-H1304	NWLxNY44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPCXXRKSzVyPUG1Mlg6OjhizszN	NULseollW0GQR1XS
KURAMOCHI	NE\1bnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1OybmlEPTB;MUWuPVcyKM7:TR?=	NF3TS\|BUSU6JRWK=
SW1783	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV75R5FuUUN3ME2xOk4xQTl\|IN88US=>	NUXrOmJEW0GQR1XS
EGI-1	NUnwfFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTF4LkWzOlUh\|ryP	NUTVVXR5W0GQR1XS
KGN	NWrTVmFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTF4LkW1PFYh\|ryP	MV\TRW5ITVJ?
PANC-03-27	NWjBb4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP0TWM2OD1zNj63OlYzKM7:TR?=	NGjDfJZUSU6JRWK=
RH-1	M2rzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXWwcIV{UUN3ME2xOk45OjVizszN	NFXjTpNUSU6JRWK=
HT-1376	NH7ObFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\DNYtKSzVyPUG2Mlg1PDZizszN	NVG4SIp2W0GQR1XS
ZR-75-30	NXPUeIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NISxRmRKSzVyPUG2Mlk{PjFizszN	MUDTRW5ITVJ?
TI-73	NWT5PZczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\E[GlEPTB;MU[uPVQxQCEQvF2=	NVP4OpdwW0GQR1XS
TK10	NXfz[\|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnuzTWM2OD1zNz6wNFc6KM7:TR?=	NXHH[XZYW0GQR1XS
SW684	M1HnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTF5LkCxOVQh\|ryP	NYrUend[W0GQR1XS
RPMI-8866	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHwbIJKSzVyPUG3MlA3QTlizszN	NWfLbmNoW0GQR1XS
LNCaP-Clone-FGC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTF5LkWyNFEh\|ryP	MkHxV2FPT0WU
NCI-H2291	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTF6LkSzOFUh\|ryP	MUPTRW5ITVJ?
T47D	M17YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFizV3NKSzVyPUG4MlQ5QCEQvF2=	M4\XSnNCVkeHUh?=
A204	NUDwOYt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nEW2lEPTB;MUiuOVQ2OiEQvF2=	MVnTRW5ITVJ?
HT-144	NHTUUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrydlFmUUN3ME2xPE44PDJ5IN88US=>	NV35dnRuW0GQR1XS
MDA-MB-361	NFvuPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17vfGlEPTB;MUmuNFcyPCEQvF2=	M3\QSHNCVkeHUh?=
HCC1806	NWHwOHBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEG4cVRKSzVyPUG5MlE2QTFizszN	M{nVW3NCVkeHUh?=
NCI-H596	NXjTSmNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4P2SWlEPTB;MUmuOlM6OSEQvF2=	NGDzcGxUSU6JRWK=
K-562	M2PXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fQWmlEPTB;MUmuPFkzPiEQvF2=	NX\WR\|doW0GQR1XS
D-336MG	M{D1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn31TWM2OD1zOT65N\|IzKM7:TR?=	MV;TRW5ITVJ?
SK-MEL-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17vUWlEPTB;MkCuNVU2QSEQvF2=	NV:z[XFtW0GQR1XS
HEC-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJyLkS5O\|gh\|ryP	NGTWR4ZUSU6JRWK=
EW-13	NWO5d2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfvcWRKSzVyPUKwMlU1PDNizszN	NIrkUJZUSU6JRWK=
Hs-578-T	NEPKcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[0TWM2OD1{MD61OVg{KM7:TR?=	NYPSSXQ3W0GQR1XS
SJSA-1	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rRZmlEPTB;MkCuOVY5QCEQvF2=	NFfDSFRUSU6JRWK=
RCC10RGB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfDdoVKSzVyPUKwMlY4OTlizszN	M{nYSXNCVkeHUh?=
LAN-6	NEnYVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTJzLkCzPVYh\|ryP	NYDleplyW0GQR1XS
NCI-H1048	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;5S2lEPTB;MkGuNlI2QCEQvF2=	MkfYV2FPT0WU
CW-2	NHHqXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDUTWM2OD1{MT6yO\|A2KM7:TR?=	MWjTRW5ITVJ?
HCC2157	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjZSJVKSzVyPUKxMlM3KM7:TR?=	MXTTRW5ITVJ?
EW-22	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C0NWlEPTB;MkGuN\|c3KM7:TR?=	NVv1d\|V[W0GQR1XS
A253	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LY[GlEPTB;MkGuOFQ5OSEQvF2=	NV\L[WVUW0GQR1XS
BE-13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fCTWlEPTB;MkGuOlEyOyEQvF2=	NHz3S5VUSU6JRWK=
KINGS-1	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlj6TWM2OD1{MT62N\|E3KM7:TR?=	NXG1TVlYW0GQR1XS
ETK-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rxXWlEPTB;MkGuPFE2OiEQvF2=	MljRV2FPT0WU
NCI-H2452	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G2[mlEPTB;MkGuPFY1PyEQvF2=	M{TqNnNCVkeHUh?=
HPAF-II	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjLcIVKSzVyPUKxMlg6OjNizszN	NWP2TGRMW0GQR1XS
D-542MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jkfmlEPTB;MkGuPVA3QSEQvF2=	M{HKVnNCVkeHUh?=
NCI-H630	NITyNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTJ{LkCyPVYh\|ryP	NGX5Z2VUSU6JRWK=
TGBC11TKB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ{LkC0PUDPxE1?	MoG2V2FPT0WU
BCPAP	NWD6O3loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljVTWM2OD1{Mj62NVEh\|ryP	MlnBV2FPT0WU
HLE	M3XlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[0Z2lEPTB;MkKuOlk4KM7:TR?=	MUfTRW5ITVJ?
NCI-H727	M323[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TNSGlEPTB;MkKuO\|M2KM7:TR?=	MW\TRW5ITVJ?
RD	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHVUGVKSzVyPUKyMlc2OThizszN	MUPTRW5ITVJ?
NCI-H522	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3rTWM2OD1{Mj64OFMyKM7:TR?=	MXLTRW5ITVJ?
CGTH-W-1	NH;NXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\QOopKSzVyPUKzMlA3PDFizszN	Mn7lV2FPT0WU
SK-LU-1	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfaNZdYUUN3ME2yN{41Pjh\|IN88US=>	NIToeo9USU6JRWK=
BB65-RCC	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvFV4p{UUN3ME2yN{44QDZ\|IN88US=>	NGXHO5JUSU6JRWK=
HSC-3	NXTGTGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvwWppKSzVyPUKzMlg2OjdizszN	NUC3NmtIW0GQR1XS
SK-MES-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHq0bI1KSzVyPUK0MlAyPjFizszN	NVrvRphiW0GQR1XS
DB	NUTDd3VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTJ2LkGwNlgh\|ryP	MY\TRW5ITVJ?
HO-1-N-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLwTWM2OD1{ND6zNFk{KM7:TR?=	NVXPSoJ5W0GQR1XS
MKN1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJ2Lk[4JO69VQ>?	MXvTRW5ITVJ?
MN-60	M4HUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL5TWM2OD1{ND64OVE6KM7:TR?=	M3u3bHNCVkeHUh?=
8505C	NWLzPWVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\TdVFKSzVyPUK1MlE5PDVizszN	NWrTOlhMW0GQR1XS
COLO-320-HSR	NXfkSZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP1TWM2OD1{NT6yNlA5KM7:TR?=	MmniV2FPT0WU
BB30-HNC	NFn0PGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\0TWM2OD1{NT6yOFg{KM7:TR?=	M2\CW3NCVkeHUh?=
KM12	NViwRoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXSO5FKSzVyPUK1MlU5ODdizszN	M4rLO3NCVkeHUh?=
NB13	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnuRpNLUUN3ME2yOU42QDl6IN88US=>	NGf4XVdUSU6JRWK=
HCC2998	NFPhUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJ4LkCyPFMh\|ryP	NXjOZXlEW0GQR1XS
U-118-MG	M1jURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrUdZR1UUN3ME2yOk4xQDB6IN88US=>	MV7TRW5ITVJ?
NB10	M1m5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJ4LkKzOEDPxE1?	NWrmNmN{W0GQR1XS
SK-LMS-1	NHXJO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjNW3R3UUN3ME2yO{4xPzB2IN88US=>	MYDTRW5ITVJ?
SW1573	NUHiVmF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJ5LkGxJO69VQ>?	NYnSN5ZtW0GQR1XS
LB373-MEL-D	NHG3XoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j3TWlEPTB;MkeuNVI6PCEQvF2=	MX7TRW5ITVJ?
DK-MG	NIXJRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TCbGlEPTB;MkeuNVgyPyEQvF2=	M3my[3NCVkeHUh?=
RMG-I	M3iyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vrXGlEPTB;MkeuNlAzQSEQvF2=	NVf0cYFqW0GQR1XS
SW1088	NHXLS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHWzSJRKSzVyPUK3MlUxPDJizszN	NIXLXpRUSU6JRWK=
SK-OV-3	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3qTWM2OD1{Nz63OVk{KM7:TR?=	MVfTRW5ITVJ?
KP-N-YN	M2jKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LsbmlEPTB;MkeuPFA1OyEQvF2=	NV;oWXhxW0GQR1XS
RPMI-7951	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[5dXVIUUN3ME2yPE4zPDV4IN88US=>	NH7rWWVUSU6JRWK=
CaR-1	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jqbWlEPTB;MkiuOVU5OiEQvF2=	M1rKe3NCVkeHUh?=
MKN7	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJ6LkW5OlQh\|ryP	NX;HTYtEW0GQR1XS
CHP-212	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnSTWM2OD1{OD63OFAyKM7:TR?=	NVG1OIF5W0GQR1XS
KYSE-450	M3roV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTyOHhKSzVyPUK4MlgxQTFizszN	M4HJZXNCVkeHUh?=
RXF393	NYTzbWRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTJ7LkK5NFYh\|ryP	MULTRW5ITVJ?
P30-OHK	NU\EbmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD0RpFQUUN3ME2yPU4{ODR6IN88US=>	NUP6e3BrW0GQR1XS
Ca9-22	NHXhU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rhTWlEPTB;MkmuOFI6QSEQvF2=	MXvTRW5ITVJ?
RT-112	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWWxNpEzUUN3ME2yPU41PjFzIN88US=>	MXjTRW5ITVJ?
ES1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETC[oRKSzVyPUK5Mlg2PDRizszN	M1Lab3NCVkeHUh?=
HCE-4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTOb2RMUUN3ME2yPU45Pzh4IN88US=>	MmLuV2FPT0WU
AM-38	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNyLkC2NFYh\|ryP	NICyb5JUSU6JRWK=
AsPC-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTNyLkiwOVMh\|ryP	NXHEdXZMW0GQR1XS
TE-9	NWnZNnNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\6SGlEPTB;M{CuPFc{PyEQvF2=	MlrUV2FPT0WU
HuP-T4	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3XbWQ2UUN3ME2zNE46PjN6IN88US=>	NW[yc3M1W0GQR1XS
LB2518-MEL	NX76U2FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nVOWlEPTB;M{GuNFc1PCEQvF2=	NEjq[Y5USU6JRWK=
NCI-H1703	NF30c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LR[2lEPTB;M{GuNFkxPSEQvF2=	M2S3eHNCVkeHUh?=
NCI-H2228	M4XwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTNzLkS2OVEh\|ryP	NHu2N5JUSU6JRWK=
SCC-4	M4XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;lW2dCUUN3ME2zNU46OThzIN88US=>	NFvnUZdUSU6JRWK=
KNS-81-FD	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTqPG1QUUN3ME2zNk4xOTJ6IN88US=>	MWfTRW5ITVJ?
NTERA-S-cl-D1	M13uOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrM[JhLUUN3ME2zNk4xPzN7IN88US=>	MULTRW5ITVJ?
Daoy	NHj4N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjCco5KSzVyPUOyMlA5OzhizszN	MVvTRW5ITVJ?
ES4	NYfremVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ntemlEPTB;M{KuN\|kzOiEQvF2=	MmXJV2FPT0WU
MHH-ES-1	M{jMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\iTWM2OD1\|Mj60PFczKM7:TR?=	MnL1V2FPT0WU
C-33-A	NHfZcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\qSo9KSzVyPUOyMlc4OjhizszN	M4TWdXNCVkeHUh?=
BHY	NVzSc3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jlNGlEPTB;M{KuPVQ6PSEQvF2=	M1f4eHNCVkeHUh?=
Detroit562	Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkmwTWM2OD1\|Mz62OlU4KM7:TR?=	NGW1TZZUSU6JRWK=
EW-1	NEf4[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTN\|LkmzNlIh\|ryP	M170S3NCVkeHUh?=
NCI-H1395	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTVTWM2OD1\|ND6wO\|k6KM7:TR?=	MWLTRW5ITVJ?
KM-H2	NV\sXXo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;VTWM2OD1\|Nj60O\|Q{KM7:TR?=	MYTTRW5ITVJ?
NCI-H520	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjqfGJKSzVyPUO2Mlc2PDFizszN	Mn\3V2FPT0WU
D-392MG	M2XjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Tw[mlEPTB;M{euN\|M1PCEQvF2=	MUfTRW5ITVJ?
NOMO-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkiyTWM2OD1\|Nz64NFg6KM7:TR?=	NUj0cFduW0GQR1XS
TE-6	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DSU2lEPTB;M{iuNVI1KM7:TR?=	M1fi[HNCVkeHUh?=
HT-3	M2PnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTN6LkS0N\|Yh\|ryP	MYHTRW5ITVJ?
RPMI-8226	M2\tdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT3bYV4UUN3ME2zPE46PTF7IN88US=>	MVrTRW5ITVJ?
U251	NFWzU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLlTWM2OD1\|OT6wNVI1KM7:TR?=	M1nvSnNCVkeHUh?=
GCT	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTN7LkG4OVIh\|ryP	M{P3cnNCVkeHUh?=
A431	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H5T2lEPTB;M{muNVg6PCEQvF2=	M1TD[XNCVkeHUh?=
TE-12	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXMTWM2OD1\|OT6yOFQ5KM7:TR?=	MWrTRW5ITVJ?
HMV-II	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTN7LkWwOFch\|ryP	NX3BNGZ6W0GQR1XS
IST-MES1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnuSHFFUUN3ME20NE4yPTB{IN88US=>	NYnKVmNLW0GQR1XS
SW13	NYHRXJo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XZO2lEPTB;NECuOVE6KM7:TR?=	M1flbXNCVkeHUh?=
SF295	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTRyLkiwOlYh\|ryP	NGnUdpdUSU6JRWK=
MDA-MB-157	NHrQRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\PNGlEPTB;NECuPVQ3OiEQvF2=	NFP0XpVUSU6JRWK=
TE-1	M3LYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLKd5VKSzVyPUSxMlg4OTRizszN	NWS2eFdiW0GQR1XS
HuCCT1	NV36SnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTR{LkWyPFkh\|ryP	NXz2UYVTW0GQR1XS
KYSE-510	NEOyenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjMd4ttUUN3ME20N{4yPzV2IN88US=>	MoPkV2FPT0WU
NCI-H358	NVjk[XZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTR2LkCzNFQh\|ryP	M2rZPXNCVkeHUh?=
SW900	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rnUGlEPTB;NESuNFc2QCEQvF2=	MUnTRW5ITVJ?
CAS-1	NW\VVXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTR2LkC5PVEh\|ryP	MkTuV2FPT0WU
TE-8	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjabFFQUUN3ME20OE42PjV6IN88US=>	M{D6NnNCVkeHUh?=
P12-ICHIKAWA	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDxZnk6UUN3ME20OE43OTF{IN88US=>	NY[xeFB3W0GQR1XS
YKG-1	NGjMWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTR2Lke4NUDPxE1?	MlmxV2FPT0WU
SNU-C2B	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2i5XWlEPTB;NESuO\|kxOyEQvF2=	MmewV2FPT0WU
LCLC-103H	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DjWGlEPTB;NESuPFcxOyEQvF2=	M3rCSnNCVkeHUh?=
U-87-MG	NGfu[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV25bIxqUUN3ME20OU4yODJ{IN88US=>	NVK4OWwzW0GQR1XS
HAL-01	NXvsbZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTR3LkGzO\|kh\|ryP	NXm4VnZvW0GQR1XS
OVCAR-8	Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3UTWM2OD12NT6zOVY1KM7:TR?=	NITyWGZUSU6JRWK=
KYSE-150	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTR5LkGwOVIh\|ryP	NXHGfYJoW0GQR1XS
OE33	NWq5XI9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHIUmRsUUN3ME20O{4yPDJ7IN88US=>	M4SxbHNCVkeHUh?=
CAL-62	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jhRWlEPTB;NEeuOFA3QCEQvF2=	NG\GNFBUSU6JRWK=
TCCSUP	NIfHOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHnTWM2OD12Nz62NlY1KM7:TR?=	M3\q[3NCVkeHUh?=
H4	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq4[VdpUUN3ME20O{43PjJzIN88US=>	NWjMOXJYW0GQR1XS
CP66-MEL	NUHleGlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HVSWlEPTB;NEiuNFcxPCEQvF2=	NETHeFdUSU6JRWK=
SNB75	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTR6LkG4O\|Qh\|ryP	M3jqOHNCVkeHUh?=
Mo-T	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DKcmlEPTB;NEiuNlc6KM7:TR?=	NWDwc3I6W0GQR1XS
BT-549	NFv3XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTMTWM2OD12OD6zO\|I6KM7:TR?=	M3LYe3NCVkeHUh?=
IGR-1	Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTR6Lk[2OFUh\|ryP	NHPJNoRUSU6JRWK=
NCI-H1299	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2j1eGlEPTB;NEiuO\|I1QCEQvF2=	NXniRpE6W0GQR1XS
ALL-PO	NHTJU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTxbJhsUUN3ME20PU46OjZ6IN88US=>	MUPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:^[2]	+ Expand Cell lines: SW620, LoVo, V3-YAC and V3 cells Concentrations: 0.5 μM or 1 μM Incubation Time: 17 hours Method: The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Female rude mice bearing SW620 xenografts Formulation: Sterile 0.9% sodium chloride solution Dosages: 10 mg/kg Administration: Intraperitoneally administrated (Only for Reference)

Cell Research:^[2]

+ Expand

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method: The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.
(Only for Reference)

Animal Research:^[2]

+ Expand

Animal Models: Female rude mice bearing SW620 xenografts
Formulation: Sterile 0.9% sodium chloride solution
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents individually and in order: 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years -20°C powder
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Choose Your Country or Region

By Signaling Pathways

By product type